GENEVAX IL-12-4532(Drexel University)

A phase Ib partially blinded pilot study to evaluate the safety and immunological effects of PENNVAX-B with or without co-administration of constructs containing DNA encoding for the expression of either IL-12 or IL-15.
Primary objectives
To determine the safety of HIV-1 DNA constructs (PENNVAX-B).
To determine the safety and optimal doses of the IL-12 and the IL-15 adjuvant constructs when given with PENNVAX-B.
Secondary objectives
To compare the various vaccine groups for their immunological responses to several HIV-1 antigens, utilizing the ELISPOT assay.
To analyze antibody responses to the vaccine antigens over time.
To measure CD8 cell proliferative responses to vaccine antigens over time.